BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. today announced that the Company will participate in the 12th Annual BIO CEO & Investor Conference, to be held February 8th - 9th in New York City. Christian Itin, Ph.D., the Company's President and CEO, will present a 25 minute corporate overview on February 9th at 11:00 AM ET.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
Micromet, Inc.
